SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves better-than-expected quarterly results, raised outlook and large AI-compute backlog have renewed confidence in demand, while managements customer-prepayment and contract-backed financing plans addressed some concerns about funding expansion. Traders are broadly celebrating the rebound and speculating about short covering, though skeptics continue to question the companys debt, interest costs, heavy capital spending and dilution risk.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff is dominated by concern over the investigation into CEO Jensen Huangs reported relationship with a woman suspected of ties to Chinese intelligence, and whether it raises governance, national-security or leadership risks. Traders are divided between viewing the situation as a serious threat to confidence and treating it as noise or an oversold dip, with some looking for a rebound.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and earnings call are driving attention, with traders focused on improved profitability and margins, Samsung licensing revenue, and contracted licensing from Micron. Many are bullish on the stronger financial outlook, while others question the results against elevated estimates and flag lower product sales; talk of an SK Hynix deal or Nasdaq uplisting remains speculation.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two shares are drawing attention after rising despite a quarterly bookings miss, as traders focus on managements comments that GTA VI preorders are far exceeding expectations and on the games upcoming launch. The community is bullish on the sales potential, while some traders warn that high expectations may already be priced in and debate whether the launch could prompt a sell-the-news reaction.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Attention is centered on Infleqtions upcoming quarterly results, with traders looking for updates on revenue and guidance, customer wins, and quantum-computing milestones. Bulls see the companys commercial products and diversified quantum business as potential differentiators, while skeptics question near-term execution and note that the shares remain volatile alongside the broader quantum and tech sectors.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNavs latest earnings beat drew attention, but traders are focused on the share-price drop despite a positive call and results. The broader debate remains over the delayed FCC decision on its spectrum proposal: bulls point to SpaceXs support and a possible NPRM, while skeptics see regulatory uncertainty and timing delays as major risks.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroups quarterly results topped expectations, but the shares fell anyway, prompting debate over the disconnect. Traders are weighing strength in services and profitability against pressure in the card business, higher credit-loss provisions, and spending needs, while many view the pullback as a buying opportunity and others remain bearish.

Bitdeer Technologies Group engages in the cryptocurrency mining industry. It generates income through its proprietary mining datacenters. The firm handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The company was founded by Wu Jihan in December 2021 and is headquartered in Singapore.

Bitdeer Technologies Group. - Ordinary Shares - Class A

Bitdeer Technologies Holding Co

Bitdeers earnings are driving attention: traders are weighing strong revenue growth and expansion in bitcoin mining and AI infrastructure against an earnings miss, continuing losses, and concerns about debt and possible dilution. The reaction is divided, with some viewing the selloff as a buying opportunity and others warning that financing needs and weak sector sentiment could keep pressure on the shares.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Quantinuums finalized federal CHIPS R&D award and reported U.S. equity stake are drawing attention, alongside discussion of its quantum error-correction results and Oracle and NVIDIA partnerships. Bulls view the developments as validation of its technology and position in the quantum sector, while skeptics question its valuation, commercial prospects and potential lockup-related selling.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zetas strong quarterly results and raised guidance are driving bullish attention, with traders also citing analyst upgrades and renewed momentum. Many are celebrating the advance and looking for a breakout, while others note volatile post-earnings trading and persistent resistance near a key level.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM

NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA EARLIER IN THE CARDIOVASCULAR RISK CONTINUUMPR NewswireTHOUSAND OAKS, Calif., Nov. 9, 2026 Independent VESALIUS-CV...

Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated

Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays ElevatedPR NewswireVANCOUVER, BC, Nov. 9, 2026 VANCOUVER, BC, Nov. 9, 2026 /PRNewswire/ -- Stock Preachers News Commentary- Wall Street...

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?

Key PointsAmgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases...

REPATHA LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY

REPATHA LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY REPATHA LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDYPR NewswireTHOUSAND OAKS, Calif., Nov. 5, 2026 Findings Represent Largest and Most Rigorous Head-to-Head...

Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story

Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings StoryPR NewswireNEW YORK, Nov. 4, 2026 NEW YORK, Nov. 4, 2026 /PRNewswire/ --Fly on Wall Street News Commentary- Wall Street's major indexes...

Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8%

Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8% Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8%PR NewswireVANCOUVER, BC, Nov. 4, 2026 VANCOUVER, BC, Nov. 4, 2026 /PRNewswire/ -- Stock Preachers News Commentary- Wall Street roared higher this...

AMGN Q3 Earnings Call Highlights Pipeline and Raised Outlook

Amgen raises its 2026 outlook after Q3 earnings and revenue beat estimates, as IMDELLTRA advances and MariTide offers potential long-term growth opportunities.

$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 2.06% on an annualized basis producing an average annual return of 14.83%. Currently, Amgen has a market capitalization of $249.37 billion.read more...

AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance

Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key drug portfolios and raised 2026 guidance.

• Reported GAAP EPS of $6.45 up 14.36% YoY
• Reported revenue of $10.37B up 8.45% YoY
• Amgen expects full-year 2026 total revenues in the range of $38.9B to $39.7B, GAAP EPS of $18.34 to $19.28, and non-GAAP EPS of $22.90 to $23.70.

Amgen reported Prolia and XGEVA sales declines as multiple biosimilars launched globally, free cash flow of $3.7B versus $4.2B driven by working-capital changes, and an FDA withdrawal request for TAVNEOS.

Amgen reported 8% Q3 revenue growth, Phase 3 IMDELLTRA survival and progression-free-survival benefits, and statistically significant Week 48 systemic-disease activity improvements with dazodalibep.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Investors are watching for possible SLS009 updates as Sellas expects Q4 topline results from its Phase 2 study in newly diagnosed AML.</li><li>Sellas has a 600-square-foot booth at the Dec.12 to Dec.15 ASH meeting in New Orleans, in the same hall as several major drugmakers.</li><li>Q3 holdings disclosures showed stake increases by Pictet, Swiss Life, Arizona State Retirement System and Xponance.</li></ul>Shares of Sellas Life Sciences (SLS) snapped a four-day losing streak on Tuesday as retail investors looked ahead to abstracts from the American Society of Hematology (ASH), while fresh filings revealed increased holdings by Swiss asset managers and Arizona State Retirement System.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped nearly 4% on Tuesday to $8.70.&nbsp;<h2 class="st-heading-2">SLS Bulls Count Down To ASH Abstracts</h2>ASH will release regular meeting abstracts on Wednesday, with late-breaking abstracts following on Dec.7.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.hematology.org/Meetings/Annual-Meeting/Abstracts?utm_source=chatgpt.com">&nbsp;</a>Sellas investors are watching for possible updates on SLS009, or Tambiciclib, its CDK9 inhibitor being studied in acute myeloid leukemia (AML). In August, Sellas said it expected fourth-quarter topline results from its Phase 2 study of SLS009 in newly diagnosed AML.&nbsp;The releases set the stage for the 68th ASH Annual Meeting and Exposition, running Dec.12 to Dec.15 in New Orleans. The event brings together blood-disease specialists, researchers and drugmakers, with more than 275 exhibitors expected.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.hematology.org/meetings/annual-meeting?utm_source=chatgpt.com">&nbsp;</a>Sellas has a 600-square-foot booth at the far end of Hall G, directly beside the poster area. Its 20-by-30-foot space, Booth 138, puts it in the same hall as large exhibits from Eli Lilly, Takeda, Genentech and AstraZeneca.&nbsp;Pfizer, Merck, Sanofi, AbbVie and Bristol Myers Squibb have booths across other halls, while Johnson &amp; Johnson is in Hall J, farther from Sellas. The broader exhibitor lineup includes GSK, Novartis, Amgen, Novo Nordisk, Daiichi Sankyo, Astellas, and Gilead and Kite Oncology.<h2 class="st-heading-2">Swiss Managers And Arizona Pension Raise Stakes</h2>Several institutional investors increased their stakes in Sellas during the third quarter, according to Sept.30 holdings disclosed in Tuesday filings tracked by Fiscal.ai.Pictet Asset Management Holding SA raised its stake by 15%, adding 3,704 shares to hold 27,688. Swiss Life Asset Management increased its stake by nearly 10%, adding 1,168 shares to bring its total to 13,292.Meanwhile, Arizona State Retirement System added 5,839 shares, lifting its holding by 12% to 55,391. Xponance increased its position by 3% to 19,025 shares.<h2 class="st-heading-2">Sellas’ Regal Enters Final Analysis Stage</h2>Sellas announced last week that its Phase 3 Regal trial had reached the prespecified 80th event, or death, clearing the way for database lock, unblinding and final statistical analysis.The randomized trial is testing Galinpepimut-S (GPS) as maintenance treatment for AML patients in second complete remission. Its primary endpoint is overall survival. “Reaching the 80th event represents a critical milestone in the REGAL trial,” CEO Angelos Stergiou said. Sellas expects preliminary topline results this quarter but has not set a release date.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS jumped to ‘extremely bullish’ from ‘bullish’ levels a day ago amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_732ac022d2.png" alt="sls ss.png" width="643" height="340"><figcaption>SLS sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Bio_buyout/message/668064034">anticipates</a> SLS009 data in the abstract release and said that the drug’s potential “should alone be 5X our current market Cap.” Another user&nbsp;<a href="https://stocktwits.com/Ewebb1018/message/668061540">said</a>, “it is not far fetched to think we may see data relating to GPS Expanded Access Program, and even more likely to see data regarding SLS-009.”<stembedurl>https://stocktwits.com/Ewebb1018/message/668061540</stembedurl>A separate trader also&nbsp;<a href="https://stocktwits.com/Cheffinance/message/668061442">distinguished</a> the ASH release from the pending Regal readout. “tomorrow they can say something about sls009, not about regal”<a href="https://stocktwits.com/Cheffinance/message/668061442">&nbsp;</a><stembedurl>https://stocktwits.com/Cheffinance/message/668061442</stembedurl>Institutional ownership also drew attention. “Institutions just keep loading up,” another user&nbsp;<a href="https://stocktwits.com/robcarroll/message/668067161">said</a>.<stembedurl>https://stocktwits.com/robcarroll/message/668067161</stembedurl>SLS stock has risen 135% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/super-micro-s-q1-revenue-nearly-quadruples-to-20-b-on-surging-ai-server-demand/cNGhsPWR9dk">Super Micro’s Q1 Revenue Nearly Quadruples To $20B On Surging AI Server Demand&nbsp;</a>

In this photo illustration, the SELLAS Life Sciences Group logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ASH will release regular meeting abstracts on Wednesday, followed by late-breaking abstracts on Dec.7.

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

Abbvie Inc

Bristol-Myers Squibb Co.

Glaxosmithkline plc - ADR

iShares Biotechnology ETF

Johnson & Johnson

Lilly(Eli) & Co

Merck & Co Inc

Novo Nordisk A/S

Novartis AG

Pfizer Inc

SELLAS Life Sciences Group Inc

Sanofi-Aventis

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Track AMGN stock price, charts, news and real-time market activity on Stocktwits. Join the AMGN message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around AMGEN Inc stock.

AMGN Stock Price Today - AMGEN Inc. News, Charts, Retail Sentiment

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$5.64	--	--	N/A
Q3 '26	$5.79	$6.45	11.47%	BEAT
Q2 '26	$5.62	$6.29	11.97%	BEAT
Q1 '26	$4.77	$5.15	8.04%	BEAT
Q4 '25	$4.73	$5.29	11.73%	BEAT

Feed

News

Sentiment

Earnings

Futures

Fundamentals

Info

AMGN Earnings

Latest Earnings Results: Q3 '26

Historical Earnings